TrialESMO open2023

Ramucirumab plus erlotinib versus placebo plus erlotinib in previously untreated EGFR-mutated metastatic non-small-cell lung cancer (RELAY): exploratory analysis of next-generation sequencing results.

E B Garon et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.